PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate ...

In the vast landscape of biotechnology and endocrinology, few compounds have a backstory as serendipitous or a mechanism as ...

Preclinical studies have demonstrated that PT-141 significantly enhances sexual behavior in female rodents. Palatin Technologies, Inc. (AMEX: PTN) is developing PT-141 as an investigational treatment ...